Personalized, Adaptive, and Targeted Ischemic Condition Treatment Platform

A next-generation platform for ischemic condition treatment, integrating real-time monitoring, AI-driven personalized dosing, and targeted delivery to revolutionize patient outcomes.

The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions. However, these forms have limitations in terms of efficacy, administration, and patient specificity. The new inventive concept addresses these limitations by introducing a wearable, implantable, or injectable device that continuously monitors and adapts to a subject's KLK1 polypeptide levels, administering a customized dosage form in real-time to maintain optimal therapeutic efficacy.

The platform comprises a wearable, implantable, or injectable device that continuously monitors a subject's KLK1 polypeptide levels, medical history, and genomic profile. The device is connected to a machine learning algorithm that predicts optimal KLK1 polypeptide dosing regimens for individual subjects. The algorithm integrates real-time biometric data, genomic information, and medical history to generate a customized dosage form. The platform also includes a targeting moiety that selectively binds to ischemic tissue, allowing for targeted delivery and enhanced therapeutic efficacy. Additionally, a microneedle array or electroporation system enables efficient, pain-free delivery of the dosage form, and a sensor monitors KLK1 polypeptide levels and adjusts dosage in real-time.

The new inventive concept introduces a paradigm shift in ischemic condition treatment by integrating real-time monitoring, AI-driven personalized dosing, and targeted delivery. The wearable, implantable, or injectable device, machine learning algorithm, and targeting moiety are novel components that overcome the limitations of the original patent.

Alternative embodiments of the platform could include using different types of sensors, machine learning algorithms, or targeting moieties. Variations could also include integrating the platform with existing healthcare systems, using different forms of KLK1 polypeptides, or expanding the platform to treat other diseases.

The personalized, adaptive, and targeted ischemic condition treatment platform has significant commercial potential in the pharmaceutical and healthcare industries. The platform could be marketed as a premium product for patients requiring personalized treatment, and could also be integrated into existing healthcare systems to improve patient outcomes and reduce costs.